Urine Interleukin-37 as a Biomarker of Mortality Risk in Patients With Sepsis

NCT05640037 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 99

Last updated 2024-05-08

No results posted yet for this study

Summary

This study aims to evaluate the efficacy of IL-37 as a biomarker to predict mortality risk in adults with sepsis.

Conditions

Sponsors & Collaborators

  • Zhongnan Hospital

    lead OTHER

Principal Investigators

  • Dawei Wang, MD · Wuhan University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-23
Primary Completion
2024-03-20
Completion
2024-03-20

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05640037 on ClinicalTrials.gov